Table 3.
Malignancy
|
Stemness/CSC markers
|
Method
|
Relevance
|
Ref.
|
HCC | CD133+ interaction with lymphatic endothelial cells | Co-culture | Upregulates PD-L1 | [196] |
HCC | CK-19, SALL-4 | IHC | Positively associated with PD-L1 | [194] |
HCC | EpCAM | IHC | Negatively associated with PD-L1 | [194] |
Breast cancer | CD44hiCD24lo | Flow cytometry | High PD-L1 expression | [182] |
Breast cancer | EpCAM+CD44hi CD24lo | Flow cytometry | High PD-L1 expression | [184] |
Breast cancer | EpCAM+CD90hi | Flow cytometry | High PD-L1 expression | [184] |
Breast cancer | EpCAM+CD44hiCD24lo | Flow cytometry, IF | High PD-L1 expression; nuclear PD-L1 | [185] |
Breast cancer | Stemness score | mRNA from TCGA | Significant correlation to PD-L1 | [185] |
Breast cancer | ALDH+, CD44hi | Flow cytometry | High PD-L1 expression | [183] |
Colorectal cancer | CD44hiCD133hi | Flow cytometry | High PD-L1 expression | [182] |
Colorectal cancer | CD133+CD44+ | Flow cytometry | High PD-L1 expression | [189] |
Ovarian cancer | ALDH | qRT-PCR, IF | High PD-L1 expression | [188] |
HNSCC | CD44+ | Flow cytometry, qRT-PCR, RNA in situ hybridization | High PD-L1 expression | [191] |
Lung adenocarcinoma | CD44 | mRNA in TIMER datasets | Positively associated with PD-L1 | [186] |
NSCLC | ALDH | mRNA from TCGA, IHC | Negatively associated with PD-L1 | [192] |
Cholangiocarcinoma | ALDH | Sorting of PD-L1 cells | High ALDH+ in PD-L1lo | [193] |
Pancreatic cancer | CD44+CD133+ | IF | Positively associated with PD-L1 | [190] |
PD-1: Programmed death-1; PD-L1: Programmed death ligand 1; IHC: Immunohistochemistry; TCGA: The Cancer Genome Atlas; qRT-PCR: Quantitative real-time polymerase chain reaction; HNSCC: Head and neck squamous cell carcinoma; NSCLC: Non-small cell lung carcinoma; HCC: Hepatocellular carcinoma.